Category: What’s New in MS Research

There was an abundance of welcome news emanating from Barcelona, Spain in late September, when the world’s leading experts in MS gathered in that historic city for ECTRIMS 2025, this year’s annual meeting of the European Committee for Treatment and Research in Multiple Sclerosis.

From steps you can take (literally) to clinical trial results and laboratory investigations, this edition of “What’s New in MS Research” reports on 13 encouraging findings that bode well for people who are living with multiple sclerosis or who are at elevated risk for the neurological condition. The brief study summaries that follow cover a variety of important topics. For example, these outline how walking on a treadmill

The mood inside the Phoenix Convention Center was as bright and sunny as the Arizona weather outside when thousands of MS clinicians, researchers, individuals with MS, and others convened in late May for the annual meeting of the Consortium of Multiple Sclerosis Centers (CMSC). This upbeat mood was owed to the many advances in understanding, diagnosing, and managing multiple sclerosis, detailed in hundreds of studies presented at the meeting.

Multiple sclerosis (MS) was front and center when neurologists from across the nation gathered in San Diego in April for the annual meeting of the American Academy of Neurology (AAN). More than 180 research presentations at the meeting focused on investigational and approved medications for MS, means of monitoring the condition, and strategies for improving quality of life for people with MS.

The researchers and clinicians who gathered in late February in West Palm Beach, Florida, for the 2025 ACTRIMS Forum shared data and insights on a range of promising investigational therapies, such as Bruton’s tyrosine kinase inhibitors and chimeric antigen receptor T-cell therapy.

A new year promises to bring a wealth of new insights into the nature and management of multiple sclerosis (MS). The study summaries included in this edition of “What’s New in MS Research” highlight the broad spectrum of inquiry that is driving the progress to develop better treatments against the disease.

The world’s leading experts in multiple sclerosis (MS) gathered in Copenhagen, Denmark in September 2024 to share the results of their latest research into the causes, course, and treatment of the disease. That gathering, the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), showcased encouraging findings from a number of vital studies.

People with relapsing and progressive forms of MS now can receive Ocrevus® (ocrelizumab) via intravenous infusion or Ocrevus Zunovo™ (ocrelizumab and hyaluronidase-ocsq) by subcutaneous injection.

It wasn’t just the music that had multiple sclerosis (MS) researchers, clinicians, and advocates in an upbeat mood when they gathered in Nashville from May 29th through June 1st for the Consortium of Multiple Sclerosis Centers’ (CMSC) 2024 Annual Meeting. Rather, the positive vibes reflected the many encouraging developments in MS research reported during the CMSC’s multi-day gathering.

The astounding breadth of research being conducting into the causes, manifestations, and management of multiple sclerosis (MS) was on full display when thousands of physicians, nurses, laboratory scientists, and others gathered in Denver in April for the annual meeting of the American Academy of Neurology (AAN).